4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $29.8750.

Several research firms have commented on FDMT. Jefferies Financial Group reissued a “buy” rating and set a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Royal Bank Of Canada boosted their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Finally, Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares in the company, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,478 shares of company stock worth $1,338,369 over the last three months. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its stake in 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after acquiring an additional 2,882,508 shares during the period. State Street Corp grew its stake in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares during the period. RA Capital Management L.P. raised its holdings in shares of 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after purchasing an additional 1,060,156 shares during the last quarter. Finally, Evergreen Quality Fund GP Ltd. bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth $7,136,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Down 4.5%

Shares of FDMT traded down $0.58 during trading hours on Friday, reaching $12.31. 683,562 shares of the stock traded hands, compared to its average volume of 1,069,395. The company has a market cap of $643.57 million, a price-to-earnings ratio of -4.79 and a beta of 2.70. The stock has a fifty day simple moving average of $10.21 and a 200 day simple moving average of $9.33. 4D Molecular Therapeutics has a 52 week low of $4.11 and a 52 week high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. Analysts predict that 4D Molecular Therapeutics will post -4.14 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.